Background: Somatic symptom disorders are common, disabling and costly. Individually provided short-term psychodynamic psychotherapies (STPP) have shown promising results. However, the effectiveness of STPP for somatic symptom disorders has not been reviewed. Methods: We undertook a systematic review of randomized controlled trials and controlled before and after studies. The outcomes included psychological symptoms, physical symptoms, social-occupational function, healthcare utilization and treatment continuation. Results: A total of 23 studies met the inclusion criteria and covered a broad range of somatic disorders. Thirteen were RCTs and 10 were case series with pre-post outcome assessment. Of the included studies, 21/23 (91.3%), 11/12 (91.6%), 16/19 (76.2%) and 7/9 (77.8%) reported significant or possible effects on physical symptoms, psychological symptoms, social-occupational function and healthcare utilization respectively. Meta-analysis was possible for 14 studies and revealed significant effects on physical symptoms, psychiatric symptoms and social adjustment which were maintained in long-term follow-up. Random-effect modeling attenuated some of these relationships. There was a 54% greater treatment retention in the STPP group versus controls. Conclusion: STPP may be effective for a range of medical and physical conditions underscoring the role of patients’ emotional adjustment in overall health. Future research should include high-quality randomized and clinical effectiveness studies with attention to healthcare use and costs.

Keywords:
Psychotherapy, short-term, Somatoform, Psychotherapy, psychodynamic, Psychotherapy, psychosomatic, Psychophysiologic disorders
1.
Kroenke K: Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003;12:34–43.
2.
Aaron LA, Buchwald D: A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134:868–881.
3.
Henningsen P, Zimmermann T, Sattel H: Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003;65:528–533.
4.
Kroenke K, Rosmalen JG: Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med Clin North Am 2006;90:603–626.
5.
Kroenke K: The interface between physical and psychological symptoms. Prim Care Companion J Clin Psychiatry 2003;5(suppl 7):11–18.
6.
Sha MC, Callahan CM, Counsell SR, Westmoreland GR, Stump TE, Kroenke K: Physical symptoms as a predictor of health care use and mortality among older adults. Am J Med 2005;118:301–306.
7.
Katon W, Lin EH, Kroenke K: The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29:147–155.
8.
Kroenke K, Sharpe M, Sykes R: Revising the classification of somatoform disorders: key questions and preliminary recommendations. Psychosomatics 2007;48:277–285.
9.
O’Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K: Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980–990.
10.
Kroenke K, Swindle R: Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom 2000;69:205–215.
11.
Allen LA, Escobar JI, Lehrer PM, Gara MA, Woolfolk RL: Psychosocial treatments for multiple unexplained physical symptoms: a review of the literature. Psychosom Med 2002;64:939–950.
12.
Raine R, Haines A, Sensky T, Hutchings A, Larkin K, Black N: Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care? BMJ 2002;325:1082.
13.
Jackson JL, O’Malley PG, Kroenke K: Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 2006;11:212–222.
14.
Kroenke K: Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007;69:881–888.
15.
Woolfolk R, Allen L, Tiu J: New directions in the treatment of somatization. Psychiatr Clin North Am 2007;30:621–644.
16.
Alexander F (ed): Psychosomatic Medicine. Its Principles and Applications. New York, Norton & Co, 1950.
17.
Davanloo H (ed): Short-Term Dynamic Psychotherapy. New York, Aronson, 1980.
18.
Leichsenring F, Rabung S, Leibing E: The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 2004;61:1208–1216.
19.
Abbass AA, Hancock JT, Henderson J, Kisely S: Short-term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev 2006;4:CD004687.
20.
Cohen J: Statistical power analysis for the behavioral sciences, ed 2. Hillsdale, Erlbaum Associates, 1988.
21.
Abramson JH: WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiol Perspect Innov 2004;1:6.
22.
Rosser R, Denford J, Heslop A, Kinston W, Macklin D, Minty K, Moynihan C, Muir B, Rein L, Guz A: Breathlessness and psychiatric morbidity in chronic bronchitis and emphysema: a study of psychotherapeutic management. Psychol Med 1983;13:93–110.
23.
Sjodin I: Psychotherapy in peptic ulcer disease. Acta Psychiatr Scand 1983;307:1–90.
24.
Svedlund J, Sjodin I, Ottoson JO, Dotevall G: Controlled study of psychotherapy in irritable bowel syndrome. Lancet 1983;10:589–592.
25.
Hamilton J, Guthrie E, Creed F, Thompson D, Tomenson B, Bennett R, Moriarty K, Stephens W, Liston R: A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000;119:661–669.
26.
Monsen K, Monsen JT: Chronic pain and psychodynamic body therapy: a controlled outcome study. Psychotherapy 2000;37:257–269.
27.
Junkert-Tress B, Schnierda U, Hartkamp N, Schmitz N, Tress W: Effects of short-term dynamic psychotherapy for neurotic, somatoform, and personality disorders: a prospective 1-year follow-up study. Psychother Res 2001;11:187–200.
28.
Abbass A: Intensive short-term dynamic psychotherapy in a private psychiatric office: clinical and cost effectiveness. Am J Psychother 2002;56:225–232.
29.
Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B: The cost effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303–317.
30.
Hinson VK, Weinstein S, Bernard B, Leurgans SE, Goetz CG: Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord 2006;12:177–180.
31.
Tschuschke V, Weber R, Horn E, Kiencke P, Tress W: Ambulante psychodynamische Kurzgruppenpsychotherapie bei Patienten mit somatoformen Störungen. Z Psychiatr Psycho Psychother 2007;55:87–95.
32.
Guthrie E, Creed F, Dawson D, Tomenson B: A randomized controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry 1993;163:315–321.
33.
Jantschek G, Zeitz M, Pritsch M, Wirschin M, Klor HU, Studt HH: Effect of psychotherapy on the course of Crohn’s disease. Scand J Gastroenterol 1998;33:1289–1296.
34.
Bassett DL, Pilowsky I: A study of brief psychotherapy for chronic pain. J Psychosom Res 1985;29:259–264.
35.
Linnet J, Jemec GBE: Anxiety level and severity of skin condition predicts outcome of psychotherapy in atopic dermatitis patients. Int J Dermatol 2001;40:632–636.
36.
Hawkins J: The Role of Emotional Repression in Chronic Back Pain. A Study of Chronic Back Pain Patients Undergoing Group Psychodynamic Psychotherapy as Treatment for Their Pain (published PhD dissertation). New York, New York University, 2003.
37.
Baldoni F, Baldaro B, Trombini G: Psychotherapeutic perspectives in urethral syndrome. Stress Med 1995;11:79–84.
38.
Poulsen A: Psychodynamic, time-limited group therapy in rheumatic disease – a controlled study with special reference to alexithymia. Psychother Psychosom 1991;56:12–23.
39.
Keller W, Pritsch M, von Wietersheim J, Peter S, Osborn W, Balck F, Dilg R, Schmelz-Schumacher E, Doppl W, Jantschek G, Deter HC: The effects of psychotherapy and relaxation on the psychosocial and somatic course of Crohn’s disease: main results of the German Prospective Multicenter Psychotherapy Treatment Study on Crohn’s disease. J Psychosom Res 2004;56:687–696.
40.
Deter HC, Keller W, von Wietersheim J, Jantschek G, Duchmann R, Zeitz M, German Study Group on Psychosocial Intervention in Crohn’s Disease: Psychological treatment may reduce the need for healthcare in patients with Crohn’s disease. Inflamm Bowel Dis 2007;13:745–752.
41.
Beresnevaite M: Exploring the benefits of group psychotherapy in reducing alexithymia in coronary heart disease patients: a preliminary study. Psychother Psychosom 2000;69:117–122.
42.
Barnat MR: Short-term psychotherapy and refractory headache. Headache 1981;21:257–260.
43.
Sifneos PE: The prevalence of ‘alexithymic’ characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255–262.
44.
Nielsen G, Barth K, Haver B, Havik O: Brief dynamic psychotherapy for patients presenting physical symptoms. Psychother Psychosom 1988;50:35–41.
45.
Bassler M, Krauthauser H, Hoffmann SO: Inpatient psychotherapy with chronic psychogenic pain patients. Psychother Psychosom Med Psychol 1994;44:299–307.
46.
Abbass A: The cost-effectiveness of short-term dynamic psychotherapy. J Pharmacoeconomics Outcomes Res 2003;3:535–539.
47.
Ventegodt S, Thegler S, Andreasen T, Struve F, Enevoldsen L, Bassaine L, Torp M, Merrick J: Clinical holistic medicine (mindful, short-term psychodynamic psychotherapy complemented with bodywork) in the treatment of experienced physical illness and chronic pain. Sci World J 2007;7:310–316.
48.
Higgins JPT, Green S (ed): Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Cochrane Collaboration, 2008. www.cochrane-handbook.org (updated February 2008).
49.
Diener MJ, Hilsenroth MJ, Weinberger J: Therapist affect focus and patient outcomes in psychodynamic psychotherapy: a meta-analysis. Am J Psychiatry 2007;164:936–941.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.